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Objectives. This study was conducted to test the hypothesis that
angiotensin-converting enzyme (ACE) inhibition reduces myocar-
dial ischemia and related events after myocardial infarction (MI).
Background. The oxygen demand/supply ratio of the myocar-
dium is influenced by angiotensin II as a result of its arterial
vasoconstrictive and inotropic effects and through its interaction
with the sympathetic nervous system.
Methods. We studied 244 patients who had been included in a
double-blind, randomized, placebo-controlled, post-MI, ACE in-
hibition intervention study (Captopril and Thrombolysis Study
[CATS]). All patients underwent exercise testing before and 3 and
12 months after hospital discharge. After 1-year double-blind
treatment, all patients continued receiving single-blind placebo
for 1 month.
Results. Total exercise time increased in both groups after 3
months (placebo: 186 6 13 s; captopril: 169 6 12 s, p 5 0.8
between groups) and increased further after 1 year (placebo:
113 6 11 s; captopril: 133 6 13 s, p 5 0.7 between groups). There
were also no differences in mean ST segment depression. During
the 12 months, significantly fewer ischemia-related events oc-
curred in the captopril group (82 vs. 52, p 5 0.015). This
difference was found between 3 and 12 months but not during the
first 3 months. After withdrawal from double-blind medication,
nine ischemic events were reported in the captopril group com-
pared with one in the placebo group (p 5 0.006 between groups).
Conclusions. The present data show that captopril may reduce
the incidence of ischemia-related events after MI, which becomes
apparent after 3 months. However, no anti-ischemic effect was
observed during exercise testing. After withdrawal from ACE
inhibition, a high incidence of clinical events occurred, suggesting
a rebound phenomenon.
(J Am Coll Cardiol 1997;30:400–5)
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The oxygen demand/supply ratio of the myocardium is influ-
enced by angiotensin II as a result of its arterial vasoconstric-
tive and inotropic effects and through its interaction with the
sympathetic nervous system. Angiotensin-converting enzyme
(ACE) inhibitors have been shown (1–4) to improve prognosis
when administered after acute myocardial infarction (MI) and
in patients with congestive heart failure (CHF). By a combi-
nation of hemodynamic and neurohumoral effects, ACE inhib-
itor therapy leads to improved left ventricular (LV) function.
In addition, ACE inhibitors may possibly reduce the incidence
of recurrent myocardial ischemia (5,6). The latter phenome-
non has not yet been fully elucidated because it is controversial
whether ACE inhibition in patients has direct anti-ischemic
effects (7–9). ACE inhibitors have been shown to inhibit
platelet aggregation and thereby reduce the release of vaso-
constrictors (thromboxane A2) (10) and stimulators of smooth
muscle proliferation (platelet-derived growth factor) (11).
Moreover, ACE inhibition inhibits the degradation of brady-
kinin, resulting in enhanced formation of prostacyclin and
nitric oxide in the endothelium (12,13). The concept that ACE
inhibitors may modify coronary vascular disease is supported
by the recently published Trial on Reversing Endothelial
Dysfunction (TREND) study (14), which showed beneficial
effects of ACE inhibition on endothelial function. Most studies
have shown that there is probably not a direct anti-ischemic
effect but a long-term effect. We therefore investigated, in a
post-MI, ACE inhibition intervention study (Captopril and
Thrombolysis Study [CATS] [15]), the anti-ischemic effects of
captopril. Patients in the CATS trial were not selected on the
basis of left ventricular dysfunction, as in other, similar studies
(Survival and Ventricular Enlargement study [SAVE] [6]).
Assessments were performed at hospital discharge and 3 and
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12 months after MI. Myocardial ischemia was evaluated by an
exercise tolerance test and by assessment of ischemia-related
events. Withdrawal effects, previously described in animal
studies after discontinuation of ACE inhibitors in stroke and
hypertension (16,17) but not been assessed after MI, were also
studied. Accordingly, we also studied the influence of discon-
tinuation of ACE inhibition after 12 months of treatment
during a 1-month (month 13) single-blind, placebo treatment
period.
Methods
Study design. A detailed description of the rationale and
design of the CATS trial has been published elsewhere (15). In
brief, CATS was a double-blind, randomized study in 298
patients with a first MI, who were treated with captopril or
placebo. The primary objective was to assess the effects of an
ACE inhibitor on LV dilation, as assessed by echocardiogra-
phy. Although very early treatment with captopril after MI did
not reduce the occurrence of early dilation, it was associated
with a reduced incidence of CHF. Patients who performed an
exercise tolerance test at discharge, which was conducted
according to the Bruce treadmill protocol, were included in
this study. Written informed consent was obtained from each
patient before entry into the study, and the protocol was
approved by the institutional review boards at all participating
hospitals.
Study objective. The primary objective was to assess the
efficacy of captopril versus placebo with regard to anti-ischemic
effects during the first 3 months and during the period between
3 and 12 months. Treatment effects were assessed by changes
in total exercise time and maximal ST segment depression
during exercise tests at 3 months and 1 year after MI, with an
exercise test at hospital discharge as baseline. Clinical isch-
emia-related events during follow-up were analyzed during the
same periods. During the 1-month single-blind placebo period,
after withdrawal from double-blind treatment (month 13),
ischemia-related events were analyzed.
Treatment protocol. Double-blind medication was initi-
ated immediately on completion of the streptokinase infusion,
provided that systolic blood pressure was stable and
$100 mm Hg. The target maintenance dose of the double-
blind study medication was 25 mg three times daily, adminis-
tered from day 2 until 1 year after MI. Concomitant therapy
with calcium antagonists or nitrates was instituted only for
specific indications (e.g., angina pectoris [AP] and hyperten-
sion). The protocol did not prohibit the use of beta-adrenergic
blocking agents for secondary prevention. The use of aspirin
was also at the discretion of the local investigator. After 1 year,
double-blind medication was stopped, and patients were
treated with single-blind placebo for 1 month.
Measurements. Exercise tolerance test. A symptom-limited
Bruce treadmill exercise test was performed before and 3 and
12 months after hospital discharge. Exercise testing was con-
ducted .8 h after the last dose of study medication. A
three-lead electrocardiogram was recorded each minute during
and until 6 min after completion of the exercise test. Standard
criteria for ischemia were used (18).
Ischemia-related events. Clinical ischemia-related events
were scored during the first 3 months, during the period
between 3 and 12 months and during the 1-month placebo
period after withdrawal (month 13). These ischemia-related
events were defined as unstable AP (UAP), recurrent MI,
percutaneous transluminal coronary angioplasty (PTCA), cor-
onary artery bypass graft surgery (CABG) and death. UAP was
defined as new-onset or worsening AP requiring hospital
admission. The clinical adverse events were reviewed by the
study directors and filed in the database. An independent data
quality committee reviewed the data on clinical end points. In
addition, the need for additional anti-ischemic medication was
scored.
Statistical analysis. According to the intention to treat
principle, all outcome analyses were based on the treatment
group to which the patients had been randomly assigned. In
case of missing values, the last observation was carried for-
ward. If not otherwise indicated, continuous variables were
compared using analysis of variance for repeated measure-
ments and categoric variables using Fisher exact test (two-
tailed). Results were considered statistically significant if p ,
0.05, using the two-sided levels of significance. Statistical
analyses were performed with SAS statistical software, version
6.08.
Results
Baseline patient characteristics (Table 1, Fig. 1). During
the enrollment period of the CATS trial, 298 patients were
included, with 149 allocated to each treatment group. Of these
298, 244 (82%) were discharged with an exercise tolerance test
(132 in the placebo group, 112 in the captopril group) (Fig. 1).
Clinical and demographic characteristics of the 244 patients
were similar to those of all 298 in the CATS cohort (15), and
there were no statistically significant differences between the
two groups (Table 1). Before hospital discharge, 15 patients in
the placebo group and 16 in the captopril group underwent
PTCA. Two patients underwent CABG in the placebo group
and three in the captopril group (p 5 NS between groups).
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AP 5 angina pectoris
CABG 5 coronary artery bypass graft surgery
CATS 5 Captopril and Thombolysis Study
LV 5 left ventricular
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
SAVE 5 Survival and Ventricular Enlargement study
SOLVD 5 Studies of Left Ventricular Dysfunction
UAP 5 unstable angina pectoris
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Exercise variables (Fig. 2). Total exercise time increased
equally during the first 3 months in both groups (placebo:
186 6 13 s; captopril: 169 6 12 s [mean 6 SEM], p 5 0.8
between groups) and increased further after 1 year (placebo:
113 6 11 s; captopril: 133 6 13 s, p 5 0.7 between groups)
(Fig. 2, top). During the first 3 months, there was a nonsignif-
icant decrease in mean ST segment depression in both groups.
After 1 year, changes in mean ST segment depression again did
not show statistically significant differences between the groups
(p 5 0.2) (Fig. 2, middle). The percent of exercise tests positive
for myocardial ischemia ($0.1-mV ST segment depression)
was also not different between groups at the three time points
(Fig. 2, bottom).
Ischemia-related events (Table 2). During the 12-month
period, 82 events were observed in the placebo group versus 52
in the captopril group (p 5 0.015). These events occurred in 56
patients (42%) in the placebo group and 38 (34%) in the
Figure 1. Baseline patient characteristics. Numbers in parentheses 5
patients randomized to placebo and captopril groups, respectively.
CABG 5 coronary artery bypass graft surgery; ETT 5 exercise
treadmill test; PTCA 5 percutaneous transluminal coronary angio-
plasty; UAP 5 unstable angina pectoris. Figure 2. Top, Change in total exercise time during Bruce treadmillprotocol. *p , 0.05, baseline versus month 3 and month 3 versus 1
year. Middle, Change in maximal ST segment depression during Bruce
treadmill protocol. *p , 0.05, baseline versus month 3 and month 3
versus 1 year. Bottom, Percent of exercise tests positive for ischemia
($0.1-mV ST segment depression) at baseline and 3 and 12 months.
p 5 NS for all comparisons. Open bars 5 placebo; hatched bars 5
captopril.
Table 1. Patient Characteristics
Placebo Group
(n 5 132)
Captopril Group
(n 5 112)
Age (yr) 59 6 1 59 6 1
Men/women 108/24 83/29
Pre-MI history of
Hypertension 22 (17%) 27 (24%)
Ischemic heart disease 11 (8%) 10 (9%)
Diabetes mellitus 10 (8%) 10 (9%)
Hyperlipidemia 9 (7%) 10 (9%)
Smoking 78 (59%) 78 (70%)
Beta-blockers 24 (18%) 23 (21%)
Calcium antagonists 20 (15%) 12 (11%)
Nitrates 15 (11%) 10 (9%)
Systolic blood pressure (mm Hg) 126 6 10 129 6 9
Diastolic blood pressure (mm Hg) 77 6 7 78 6 6
Heart rate (beats/min) 80 6 8 83 6 8
Killip class (%)
I 76 80
II 24 20
LVESVI (ml/m2) 29 6 11 27 6 12
LVEDVI (ml/m2) 60 6 14 59 6 16
Cumu alpha-HBDH 1,403 6 1,089 1,219 6 879
Data presented are mean value 6 SD or number (%) of patients. Cumu
alpha-HBDH 5 cumulative alpha-hydroxy butyrate in first 72 h; LVEDVI 5 left
ventricular end-diastolic volume index; LVESVI 5 left ventricular end-systolic
volume index; MI 5 myocardial infarction.
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captopril group. This difference between the two groups was
caused by fewer events after 3 months of treatment with
captopril because the total number of ischemic events during
the first 3 months was not significantly different between both
groups (37 vs. 31, placebo vs. captopril, respectively [i.e., in
27% of patients in both groups]). In contrast, between 3 and 12
months, the total number of ischemia-related events was
significantly higher in the placebo group (45 vs. 21, p 5 0.009,
placebo vs. captopril, respectively). The number of patients
who experienced these ischemia-related events was signifi-
cantly higher in the placebo group than in the captopril group
(placebo: n 5 42 [32%]; captopril: n 5 20 [18%], p 5 0.018).
There were no differences in the use of anti-ischemic medica-
tion (Table 3). No significant correlation between LV dilation
(and infarct size) and occurrence of ischemic events could be
made.
Withdrawal period (Table 4). In the month after with-
drawal from double-blind study medication, nine ischemia-
related events occurred in the group that had previously been
treated with captopril versus one ischemia-related event in the
placebo group (p 5 0.006) (Table 4). Antianginal medication
was prescribed in one patient in the placebo group (beta-
blocker) and in 11 in the captopril group (p 5 0.005) (beta-
blocker, n 5 2; calcium channel blocker, n 5 2; long-acting
nitrate, n 5 6; beta-blocker and long-acting nitrate, n 5 1).
Discussion
The main finding of the present study is that ACE inhibition,
when started early after MI, reduces the incidence of ischemia-
related events within the first year. This effect does not become
apparent until 3 months after MI and is not related to a
reduction in exercise-induced ischemia. Furthermore, after
withdrawal from ACE inhibition after 1 year treatment, a high
incidence of ischemia-related events is observed.
Reduction in ischemia-related events. The number of
ischemia-related events in the present study was not signifi-
cantly affected by captopril in the first 3 months but was
significantly reduced compared with placebo in the following 9
months. These findings are in line with the results from earlier
studies (5,6) that showed that long-term ACE inhibition in
patients with depressed LV ejection fraction leads to a signif-
icant and substantial reduction in the incidence of major
ischemic events. In the SAVE study (6), which studied the
effect of captopril after MI in patients with depressed LV
function (LV ejection fraction #0.40), the reduction in isch-
emic events became apparent after 12 months. In the Studies
of Left Ventricular Dysfunction (SOLVD) trial (5), patients
were required to have LV dysfunction (LV ejection fraction
#0.35), and symptomatic CHF (SOLVD treatment arm) or
asymptomatic LV dysfunction (SOLVD prevention arm). All
Table 2. Ischemia-Related Events
0–3 mo 3–12 mo Total (0–12 mo)
Placebo Captopril Placebo Captopril Placebo Captopril
PTCA 12 7 5 1 17 8
CABG 2 4 5 2 7 6
MI 1 2 1 0 2 2
AP/UAP 21 17 32 17 53 34
Death 1 1 2 1 3 2
Total 37 31 45 21* 82 52†
No. (%) of patients 36 (27%) 30 (27%) 42 (32%) 20 (18%)‡ 56 (42%) 38 (34%)
*p 5 0.009, †p 5 0.015, ‡p 5 0.018 versus placebo. Data presented are number of events, unless otherwise indicated.
AP 5 angina pectoris; CABG 5 coronary artery bypass graft surgery; MI 5 myocardial infarction; PTCA 5 percutaneous
transluminal coronary angioplasty; UAP 5 unstable angina pectoris.
Table 3. Patients With Antianginal Medication
0–3 mo 3–12 mo
Placebo Captopril Placebo Captopril
Beta-blocker 16 (12%) 18 (16%) 11 (8%) 10 (9%)
Ca antagonist 5 (4%) 10 (9%) 11 (8%) 11 (10%)
Nitrates 13 (10%) 10 (9%) 5 (4%) 1 (1%)
Beta-blocker 1 Ca antagonist 4 (3%) 2 (2%) 3 (2%) 3 (3%)
Beta-blocker 1 nitrate 11 (8%) 11 (10%) 5 (4%) 5 (4%)
Ca antagonist 1 nitrate 11 (8%) 2 (2%) 4 (3%) 1 (1%)
Triple therapy 16 (12%) 8 (7%) 9 (7%) 2 (2%)
Total 76 (58%) 61 (54%) 48 (36%) 33 (30%)
Data presented are number (%) of patients. Ca 5 calcium.
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patients were enrolled at least 3 months after MI and were
treated with enalapril. In these patients, the reduction in
ischemic events also became apparent after an interval of 66
months. In contrast, the Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto Micardico (GISSI)-3 (19) and In-
ternational Study of Infarct Survival (ISIS)-4 (20) trials showed
no reduction in ischemic events despite a much larger number
of events. This lack of effect on ischemic events may be
explained by the short-term follow-up period (5 to 6 weeks).
Taken together, these data may therefore suggest that the
reduction of ischemic events by ACE inhibitors requires a
longer exposure to the drug. In addition, the present data show
that ACE inhibition is effective in preventing coronary isch-
emic events in a nonselected post-MI cohort, of which the
majority had no CHF (21). The reduction in ischemic events
may be due to multiple beneficial effects of ACE inhibition, but
acute hemodynamic effects that include lowering of blood
pressure (i.e., reduction in afterload) and coronary vasodila-
tion are probably of lesser importance than long-term struc-
tural changes, such as an antiproliferative effect on vascular
smooth muscle, prevention of atherosclerosis progression and
myocardial hypertrophy and a favorable effect on endothelial
function (10–13,22–25). Most studies showed that there is
probably not a direct anti-ischemic effect but a long-term
effect, indicating that mechanisms such as platelet-derived
growth factor are probably the most significant factors influ-
enced by ACE inhibitors, which express their beneficial effects
after long-term treatment.
The present study shows that much of the beneficial effect
of captopril was in reducing UAP or recurrent MI, probably
related to plaque rupture. One possible mechanism of the
beneficial effects seen in this study is that captopril reduced
plaque instability (26). Such an effect would be compatible with
the slow onset of the benefits observed in the present study and
in the SAVE (6) and SOLVD (5) trials and with the observa-
tion that ACE inhibition has little if any effect on exertional AP
(27).
Absence of effect on ischemia during exercise. Captopril
treatment in this study was not associated with an overall effect
on exercise-induced ischemia. Moreover, after 3 months, pla-
cebo appeared to have a slightly more beneficial effect than
captopril (p 5 0.3), but after 12 months the reverse was
observed, again not statistically significant. These results may
be compatible with previous short-term (7–9) trials that re-
ported conflicting results on the effect of ACE inhibitors in
patients with stable AP. These three previous studies lasted
only 6 weeks to 3 months, which may correspond to the lack of
a favorable effect during the first 3 months in the present study
and may be related to the fact that ACE inhibitors induce no
or minimal changes in rate–pressure product during exercise in
normotensive patients, and the effect on myocardial oxygen
demand appears to be modest (28). Daly et al. (27) showed
that ACE inhibitors may improve exercise tolerance in patients
with a high rate–pressure product by reducing it during
exercise stress testing. In the present study, the exercise test
was done .8 h after the last dose of medication, and only
25 mg of captopril three times daily was used; thus, there is a
strong possibility that washout of captopril occurred during
exercise stress testing. Had the exercise tests been performed
during the active hemodynamic period, the effects of captopril
might have been greater and may explain some of the results of
the present study. It has been suggested (29) that when
ischemia is observed in the presence of other conditions, such
as CHF or increased neurohumoral activation, or both, the
beneficial effects of ACE inhibitors on these modulating
factors indirectly lead to a reduction in myocardial ischemia;
again, this reduction may require long-term treatment.
High incidence of ischemic events after withdrawal from
ACE inhibition. During the 1-month placebo period, a higher
incidence of ischemia-related events was reported, and more
anti-anginal medication was prescribed in patients who had
been previously been allocated to ACE inhibition. Although
this finding is in line with previous observations (30), the
number of events was small and is in contrast to the results of
previous studies of other cardiovascular disease conditions. In
a dog model of hypertension, Thybo et al. (16) showed that
when higher doses of ACE inhibition were used, a less
pronounced persistent effect after withdrawal from treatment
was observed. ACE inhibition in rats was found (17) to cause
long-lasting protection from stroke and mortality after the
treatment period. An explanation for the present findings
might be found in a substudy of the SOLVD (treatment arm)
(30). Two weeks after withdrawal from that study, 13% of
patients who had been withdrawn from enalapril developed
ischemia-related events, whereas no patients previously ran-
domized to placebo experienced an event. This result coin-
cided with an increase in LV volumes to approximately the
level observed before randomization, which might have led to
higher oxygen demand. Another possible explanation might be
the so-called rebound phenomenon that occurs after stopping
ACE inhibition. It is known that under ACE inhibition, plasma
renin activity increases, and in some organs, an elevation in
mRNA in response to ACE may occur (31). Discontinuation of
ACE inhibition results in a pronounced increase in angiotensin
II and ACE activity, risk factors for MI (32). Another possi-
bility is the decrease in bradykinin levels caused by an increase
in ACE activity after stopping ACE inhibition (23). This
decrease could have an adverse effect on the vascular wall (13).
Because the ischemic events that occur during the withdrawal
period (UAP and recurrent MI) are associated with plaque
Table 4. Ischemia-Related Events During Withdrawal Period
Placebo Captopril
PTCA 0 0
CABG 0 0
MI 0 3
AP/UAP 0 5*
Death 1 1
Total 1 9†
*p 5 0.02, †p 5 0.006 versus placebo. Data presented are number of events.
Abbreviations as in Table 2.
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rupture, the clinical beneficial effects of ACE inhibitors may be
linked to plaque stabilization, as discussed earlier.
Limitations of the study. At the time of the design of the
CATS study the beneficial effects of ACE inhibition had not
yet been as well established as they are today. In the CATS
trial, at the end of the study (month 12), echocardiography was
performed and analyzed; depending on LV dimensions, it was
decided whether treatment with captopril should be (re-)
started. Up to then, all patients were treated with placebo for
1 month, which may be questionable today.
Another limitation is that the present study was an analysis
of secondary end points, which in general require more
rigorous evaluation (33). However, these end points were
predefined in the study protocol.
Furthermore, the negative results of exercise testing do not
exclude the possibility that ACE inhibition may have an effect
on exercise-induced ischemia. It is therefore unclear whether
other methods used to evaluate ischemia, in particular imaging
techniques such as positron emission tomography, which are
more sensitive than conventional exercise testing (34), would
have detected an anti-ischemic effect, if present.
Clinical implications. Because our data are based on pa-
tients with a previous MI and not on low ejection fraction or
CHF, the observation of benefit in this cohort raises the
possibility of a wider role for ACE inhibitors in preventing
major ischemic events, possibly by plaque stabilization. This
hypothesis should be tested in prospective studies in patients
with ischemic heart disease (documented by positive exercise
test results) and preserved LV function, with a long-term
follow-up period.
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